Over 20 Innovative Drug Companies Secure Financing Rounds Exceeding $50 Million, Including China's Haobo Pharma Which Recently Filed IPO Prospectus

　　【Pharmaceutical Network Industry DynamicsAccording to relevant data statistics, in December 2024, the global biopharmaceutical field completed no less than 175 financing activities, with a total publicly disclosed financing amount exceeding $3.8 billion. Among them, more than 20 companies focused on developing innovative drugs completed single financings surpassing the $50 million mark. These include China-based AusperBio.
 

On December 27, AusperBio announced the completion of a $73 million Series B financing round. The proceeds from this round will primarily be used to advance the China and international clinical trials of its core small nucleic acid innovative drug, AHB-137, as well as preparations for early commercialization. Additionally, the funds will support the expansion of the company’s new R&D pipeline and the ongoing development and growth of the team. Relevant personnel from AusperBio stated that AHB-137, as the core drug from our self-innovated Med-Oligo™ platform, garnered significant attention and positive evaluations from the international clinical and academic communities following the release of interim data from the Phase IIa trial at the AASLD conference in November.
 

Public information shows that AusperBio focuses on the functional cure of chronic hepatitis B (HBV) and the development of highly targeted therapies for liver diseases, while also expanding into targeted small nucleic acid treatments for new targets beyond the liver. AHB-137 Injection, a non-conjugated antisense oligonucleotide (ASO) drug developed by the company with the potential for a "functional cure" of hepatitis B, has been designated as a breakthrough therapy by China's NMPA and is currently in Phase 2 clinical trials. Preclinical studies have demonstrated its ability to induce the degradation of all HBV RNA and significantly reduce HBsAg levels.
 

In addition, innovative drug development companies that received substantial financing in December 2024 also include AntagTherapeutics, a novel polypeptide therapy R&D company; NuvigTherapeutics, a novel immunotherapy R&D company; VeraDermics, a dermatological drug R&D company; AkamisBio, an anti-cancer gene therapy R&D company; OttimoPharma, a bifunctional antibody drug R&D company; and Syncromune, a metastatic solid tumor immunotherapy R&D company.
 

Among them, Antag Therapeutics announced the successful completion of an €80 million (approximately $83.29 million) Series A financing round. The proceeds will be mainly used to advance the clinical development of its lead project AT-7687 and expand Antag's once-a-month injectable therapy pipeline.
 

Nuvig Therapeutics Announces $161 Million Series B Financing to Advance Lead Candidate NVG-2089 into Clinical Proof-of-Concept Studies and Progress Preclinical Pipeline
 

Veradermics Announces $75 Million Series B Financing to Support Pivotal Clinical Studies of Lead Candidate VDPHL01 for the Treatment of Androgenetic Alopecia or Seborrheic Alopecia
 

Akamis Bio Announces $60 Million Series A Financing to Advance NG-350A Program for Phase 1b Clinical Proof-of-Concept Study in Locally Advanced Rectal Cancer Patients
 

Ottimo Pharma Announces Completion of Over $140 Million Series A Financing to Accelerate Development of Lead Candidate Jankistomig and Advance Bifunctional Pipeline
 

Syncromune Announces Successful Completion of $100 Million Series A Financing to Advance Lead Candidate SV-102 into Phase 2a Clinical Trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.